Comorbidity status and interleukin-10 levels in end-stage renal disease patients treated with hemodialysis.

Unlabelled: It has been proven that the activity of chronic inflammation is one of the leading factors in the development of comorbid pathology in endstage renal disease (ESRD) patients. However, the clinical significance of anti-inflammatory mediators in this patient population has been studied quite limited. Study the role of IL-10 in the pathogenesis of comorbidity, due to its inherent properties, causes great interest.